Metipranolol

After a compound and its various effects - or, as the case may be, any particular one of these - have been discovered there is still a long way ahead until it is available for use in daily practice as a finished product. Before reaching the doctor, the substance is examined by chemists, pharmacologists and pharmacists - just to mention a few of the most important stages in a whole research sequence. Before the drug is finally made available on the market, the findings resulting from animal experiments must be confirmed in clinical studies. The expectations involved in its development must be met, and sufficient evidence has to be established as to the drug's effects and side effects, indications and contraindications, and the questions of safe use and appropriate dosage. Only then may the drug be registered and introduced to the market. In this respect Metipranolol eye drops, which have recently been launched on the market, formed no exception and had likewise to go through all these various stages. A series of investigators at many different centers participated in this procedure, and at the invitation of the manufacturers, Messrs. Dr. Gerhard Mann, they assembled for discussions at a symposium held in Berlin in January 1983, and reported on the substance and their experiences with it.

Contenu
New Directions in Glaucoma Therapy Introductory Speech at the Metipranolol Symposium.- Receptor-mediated Effects of Drugs on the Eye.- Present Day Possibilities of Glaucoma Therapy.- Pharmacological Spectrum of Metipranolol and Experience in Clinical Use.- Suitability of Metipranolol for Glaucoma Therapy from the Pharmacological Viewpoint. Pharmacological Properties of Metipranolol in Glaucoma Therapy.- The Toxicology of Metipranolol with Particular Regard to the Eye.- Principles of Clinical Drug Trials.- The Local Anaesthetic Action of Metipranolol Versus Timolol in Patients with Healthy Eyes.- Pharmaceutical Development of Eye Drops Using the Product Betamann® as an Example.- Results of a 6 Weeks' Multicenter Double-blind Trial Metipranolol Versus Timolol.- Therapeutic Efficacy of Metipranolol Eye Drops 0.3 % Versus Timolol Eye Drops 0.25 % A Double-blind Cross-over Study.- Efficacy and Tolerance of Metipranolol Results of a Multicenter Long-term Study.- Results of a Long-term Study with Metipranolol.- Metipranolol Eye Drops Clinical Suitability in the Treatment of Chronic Open Angle Glaucoma.- Prophylaxis of an Iatrogenic Increase in Intraocular Pressure.- Regulating Pressure in Various Forms of Glaucoma with Metipranolol Eye Drops.- Supplementary Comments from the Discussion at the Metipranolol Symposium. Compiled and reviewed.